LMAT Stock Recent News
LMAT LATEST HEADLINES
BURLINGTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in June.
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ONON, PKOH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 23, 2023.
LeMaitre Vascular logged impressive sales growth in the first quarter. The company could maintain outsize payout growth in the future.
Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
LeMaitre credited a beefed-up sales force and an uptick in hospital orders for higher numbers. The company grew revenue by 19% year over year in the first quarter.
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q1 2023 Earnings Conference Call May 2, 2023 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer David Roberts - President Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Inc. Frederick Wise - Stifel, Nicolaus & Company, Inc. Michael Petusky - Barrington Research Associates, Inc. Scott Henry - ROTH Capital Partners Operator Welcome to the LeMaitre Vascular Q1 2023 Financial Results Conference Call. As a reminder, today's call is being recorded.
Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better bang for their buck right now?
ZBH vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular's results were mixed in the fourth quarter. The company could maintain high dividend growth moving forward.